Vinflunine
A chemotherapeutic agent used in cancer treatment
| Vinflunine | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Vinflunine is a chemotherapeutic agent used in the treatment of various types of cancer. It is a vinca alkaloid derivative, specifically designed to improve upon the efficacy and safety profile of its predecessors, such as vincristine and vinblastine.
Mechanism of Action[edit | edit source]
Vinflunine works by inhibiting microtubule assembly, which is crucial for cell division. By disrupting the microtubule dynamics, vinflunine effectively halts the mitotic process, leading to apoptosis of the cancer cells. This mechanism is similar to other vinca alkaloids, but vinflunine has been modified to enhance its binding affinity and reduce neurotoxicity.
Clinical Use[edit | edit source]
Vinflunine is primarily used in the treatment of urothelial carcinoma, particularly in patients who have previously been treated with platinum-based chemotherapy. It has also been investigated for use in other types of cancer, including non-small cell lung cancer and breast cancer.
Side Effects[edit | edit source]
Common side effects of vinflunine include neutropenia, anemia, constipation, and fatigue. Less common but serious side effects can include cardiotoxicity and neurotoxicity. Patients undergoing treatment with vinflunine require regular monitoring of their blood cell counts and organ function.
Pharmacokinetics[edit | edit source]
Vinflunine is administered intravenously and has a complex pharmacokinetic profile. It is extensively metabolized in the liver, primarily by the cytochrome P450 enzyme system. The drug and its metabolites are excreted mainly through the biliary route.
Development and Approval[edit | edit source]
Vinflunine was developed by Pierre Fabre Laboratories and received approval for use in the European Union in 2009. It is not approved by the Food and Drug Administration (FDA) for use in the United States.
Related pages[edit | edit source]
Vinflunine
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
